Re­silience starts the year with its first deal out­side of North Amer­i­ca

Man­u­fac­tur­ing com­pa­ny Re­silience hit sev­er­al high points in 2022 in se­cur­ing an­oth­er fund­ing round and net­ting part­ner­ships with ma­jor play­ers, and now it’s start­ing the new year with a deal that moves it out­side North Amer­i­ca for the first time.

On Tues­day, Re­silience an­nounced that the Abu Dhabi-based sov­er­eign in­vestors, the Mubadala In­vest­ment Com­pa­ny, inked an eq­ui­ty in­vest­ment. The two par­ties will col­lab­o­rate on a bio­phar­ma man­u­fac­tur­ing plan to build a new man­u­fac­tur­ing fa­cil­i­ty in Abu Dhabi. As per the deal, Mubadala will es­tab­lish the fa­cil­i­ty and Re­silience will op­er­ate it. The Abu Dhabi fa­cil­i­ty will man­u­fac­ture a range of prod­ucts, in­clud­ing ther­a­pies for can­cer and in­fec­tious dis­eases, along with vac­cines and oth­er prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER